18.8%), fatigue (19.0% vs.
18.8%), vomiting (19.0% vs.
8.3%), decreased appetite (14.8% vs.
9.2%), and arthralgia (14.3% vs.
16.2%).
Grade 3 or 4 adverse events occurred in 64 patients (27.0%) who received elacestrant and 47 patients (20.5%) who received standard-of-care therapy.
The most common grade 3 or 4 adverse events in the elacestrant arm were nausea (six patients, 2.5%), back pain (six patients, 2.5%), and increased alanine aminotransferase (five patients, 2.1%).
The most common grade 3 or 4 adverse events in the standard-of-care arm were nausea, fatigue, diarrhea, and increased aspartate aminotransferase (each occurring in two patients, 0.9%).